AP2378A - Sulfonamide derivatives for the treatment of diseases. - Google Patents

Sulfonamide derivatives for the treatment of diseases.

Info

Publication number
AP2378A
AP2378A AP2006003671A AP2006003671A AP2378A AP 2378 A AP2378 A AP 2378A AP 2006003671 A AP2006003671 A AP 2006003671A AP 2006003671 A AP2006003671 A AP 2006003671A AP 2378 A AP2378 A AP 2378A
Authority
AP
ARIPO
Prior art keywords
diseases
treatment
sulfonamide derivatives
sulfonamide
derivatives
Prior art date
Application number
AP2006003671A
Other languages
English (en)
Other versions
AP2006003671A0 (en
Inventor
Alan Daniel Brown
Kim James
Charlotte Alice Louise Lane
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2378(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406388A external-priority patent/GB0406388D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AP2006003671A0 publication Critical patent/AP2006003671A0/xx
Application granted granted Critical
Publication of AP2378A publication Critical patent/AP2378A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AP2006003671A 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases. AP2378A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290168 2004-01-22
GB0406388A GB0406388D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60025904P 2004-08-09 2004-08-09
PCT/IB2005/000112 WO2005080324A1 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (2)

Publication Number Publication Date
AP2006003671A0 AP2006003671A0 (en) 2006-06-30
AP2378A true AP2378A (en) 2012-03-08

Family

ID=43063961

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003671A AP2378A (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases.

Country Status (41)

Country Link
US (1) US7351742B2 (ru)
EP (1) EP1708992B1 (ru)
JP (1) JP4036343B2 (ru)
KR (1) KR100785580B1 (ru)
CN (1) CN1910144B (ru)
AP (1) AP2378A (ru)
AR (1) AR047510A1 (ru)
AT (1) ATE369333T1 (ru)
AU (1) AU2005214154B2 (ru)
BR (1) BRPI0507041A (ru)
CA (1) CA2553293C (ru)
CO (1) CO5720993A2 (ru)
CY (1) CY1106894T1 (ru)
DE (1) DE602005001929T2 (ru)
DK (1) DK1708992T3 (ru)
DO (1) DOP2005000004A (ru)
EA (1) EA009735B1 (ru)
EC (1) ECSP066701A (ru)
ES (1) ES2289691T3 (ru)
GE (1) GEP20084452B (ru)
HK (1) HK1096083A1 (ru)
HN (1) HN2005000030A (ru)
HR (1) HRP20070452T3 (ru)
IL (1) IL176629A (ru)
MA (1) MA28303A1 (ru)
ME (1) ME00557A (ru)
MY (1) MY139690A (ru)
NL (1) NL1028086C2 (ru)
NO (1) NO20063761L (ru)
NZ (1) NZ548235A (ru)
OA (1) OA13361A (ru)
PA (1) PA8621901A1 (ru)
PE (1) PE20050765A1 (ru)
PL (1) PL1708992T3 (ru)
PT (1) PT1708992E (ru)
RS (1) RS50538B (ru)
SI (1) SI1708992T1 (ru)
TW (1) TWI273099B (ru)
UA (1) UA82283C2 (ru)
UY (1) UY28724A1 (ru)
WO (1) WO2005080324A1 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
KR20080016968A (ko) * 2005-07-18 2008-02-22 화이자 리미티드 설폰아마이드 유도체의 제조 방법
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007107828A2 (en) 2006-03-20 2007-09-27 Pfizer Limited Amine derivatives
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
KR20090050104A (ko) * 2006-10-04 2009-05-19 화이자 리미티드 아드레날린성 효능제 및 무스카린성 길항제로서 술폰아미드 유도체
DE102007018151A1 (de) 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US7713463B1 (en) * 2007-11-13 2010-05-11 Nuvasive, Inc. Method of manufacturing embroidered surgical implants
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US8263623B2 (en) * 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
DK3210981T3 (en) 2009-04-23 2019-04-01 Theravance Respiratory Co Llc DIAMIDE COMPOUNDS WITH MUSCARINE RECEPTOR ANTAGONIST AND BETA-2 ADDRESSER RECEPTOR AGONIST ACTIVITY
EP2435462A1 (en) 2009-05-29 2012-04-04 Pfizer Limited Novel glucocorticoid receptor agonists
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
PE20141614A1 (es) 2011-06-10 2014-11-20 Chiesi Farma Spa Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico
MA38147B1 (fr) 2012-12-06 2018-09-28 Chiesi Farm Spa Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
AR093832A1 (es) 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) * 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US7048994B2 (en) * 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US6747043B2 (en) * 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists

Also Published As

Publication number Publication date
TW200530164A (en) 2005-09-16
KR20060127073A (ko) 2006-12-11
HRP20070452T3 (en) 2008-02-29
US7351742B2 (en) 2008-04-01
WO2005080324A8 (en) 2006-02-23
RS50538B (sr) 2010-05-07
AU2005214154B2 (en) 2008-01-24
UY28724A1 (es) 2005-08-31
CY1106894T1 (el) 2012-09-26
NL1028086A1 (nl) 2005-07-25
DE602005001929T2 (de) 2007-12-06
PA8621901A1 (es) 2006-03-24
ECSP066701A (es) 2006-10-31
SI1708992T1 (sl) 2007-12-31
EA009735B1 (ru) 2008-02-28
JP2007518790A (ja) 2007-07-12
NZ548235A (en) 2010-05-28
BRPI0507041A (pt) 2007-06-12
CN1910144B (zh) 2010-06-09
ME00557A (en) 2011-12-20
EP1708992B1 (en) 2007-08-08
CO5720993A2 (es) 2007-01-31
ES2289691T3 (es) 2008-02-01
EP1708992A1 (en) 2006-10-11
TWI273099B (en) 2007-02-11
CA2553293A1 (en) 2005-09-01
NO20063761L (no) 2006-10-23
MA28303A1 (fr) 2006-11-01
CA2553293C (en) 2010-12-14
DE602005001929D1 (de) 2007-09-20
HK1096083A1 (en) 2007-05-25
AU2005214154A1 (en) 2005-09-01
AR047510A1 (es) 2006-01-25
HN2005000030A (es) 2009-04-20
JP4036343B2 (ja) 2008-01-23
DOP2005000004A (es) 2005-07-31
KR100785580B1 (ko) 2007-12-13
US20050171147A1 (en) 2005-08-04
IL176629A0 (en) 2006-10-31
MY139690A (en) 2009-10-30
WO2005080324A1 (en) 2005-09-01
GEP20084452B (en) 2008-08-10
CN1910144A (zh) 2007-02-07
AP2006003671A0 (en) 2006-06-30
NL1028086C2 (nl) 2006-05-09
PT1708992E (pt) 2007-11-16
ATE369333T1 (de) 2007-08-15
PE20050765A1 (es) 2005-10-31
PL1708992T3 (pl) 2007-12-31
DK1708992T3 (da) 2007-11-05
EA200601141A1 (ru) 2007-02-27
UA82283C2 (ru) 2008-03-25
OA13361A (en) 2007-04-13
IL176629A (en) 2011-04-28

Similar Documents

Publication Publication Date Title
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1768656A4 (en) TREATMENT OF OCULAR DISEASES
GB0400802D0 (en) Compounds for the treatment of disease
GB0523964D0 (en) The treatment of ophthalmic diseases
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease
ZA200606780B (en) Compounds for the treatment of diseases
HK1096379A1 (en) Sulfonamide derivatives for the treatment of diseases
GB0406387D0 (en) Sulfonamide derivatives for the treatment of diseases
GB0406388D0 (en) Sulfonamide derivatives for the treatment of diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
GB0408297D0 (en) Indole derivatives for the treatment of diseases
GB0415352D0 (en) Compounds for the treatment of disease
GB0523962D0 (en) The treatment of ophthalmic diseases
GB0523965D0 (en) The treatment of ophthalmic diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases